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CLINICAL SCIENCE

Switching to Bictegravir/Emtricitabine/Tenofovir
Alafenamide in Black Americans With HIV-1: A Randomized
Phase 3b, Multicenter, Open-Label Study
Debbie Hagins, MD,a Princy Kumar, MD,b Michael Saag, MD,c Anson K. Wurapa, MD,d
Indira Brar, MD,e Daniel Berger, MD,f Olayemi Osiyemi, MD,g Corrilynn O. Hileman, MD,h
Moti N. Ramgopal, MD,i Cheryl McDonald, MD,j Christiana Blair, MS,k Kristen Andreatta, PhD,k
Sean E. Collins, MD, MS,k Diana M. Brainard, MD,k and Hal Martin, MD, MPH,k on behalf of the
BRAAVE2020 Investigators

Background: With the highest rates of HIV/AIDS in the United
States, Black Americans are still underrepresented in HIV
medical research.

Setting: BRAAVE (NCT03631732) is a randomized, phase 3b,
multicenter, open-label US study.
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Methods: Adults identifying as Black or African American and
virologically suppressed on 2 nucleoside reverse transcriptase
inhibitors (NRTIs) plus third agent were randomized (2:1) to switch
to open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/
TAF) once daily or stay on baseline regimen (SBR) for 24 weeks,
after which SBR had delayed switch to B/F/TAF. Resistance to nonNRTIs, protease inhibitors, and/or NRTIs was permitted; integrase
strand transfer inhibitor resistance was exclusionary. Primary
endpoint was proportion of participants with HIV-1 RNA $50
copies/mL at week 24 (snapshot algorithm; noninferiority margin
of 6%).

Results: Of 558 screened, 495 were randomized/treated (B/F/TAF
n = 330; SBR n = 165). Overall, 32% were ciswomen, 2%
transwomen, and 10% had an M184V/I mutation. At week 24,
0.6% on B/F/TAF vs 1.8% on SBR had HIV-1 RNA $50 copies/mL
(difference 21.2%; 95% conﬁdence interval 24.8% to 0.9%),
demonstrating noninferiority of B/F/TAF vs SBR. Proportions with
HIV-1 RNA ,50 copies/mL at week 24 were 96% B/F/TAF and
95% SBR and remained high at week 48. No participant had
treatment-emergent resistance to study drug. Treatments were well
tolerated. Study drug-related adverse events, mostly grade 1,
occurred in 10% of participants on B/F/TAF through week 48 and
led to discontinuation in 9 participants through week 48.
Conclusions: For Black Americans with HIV, switching to B/F/
TAF was noninferior to continuing a variety of regimens, including
those with pre-existing NRTI mutations.
Key Words: bictegravir, HIV, Black Americans, tenofovir alafenamide, INSTI
(J Acquir Immune Deﬁc Syndr 2021;88:86–95)

INTRODUCTION
Among racial and ethnic groups in the United States,
Black people have the highest incidence and prevalence of
HIV/AIDS.1,2 Black Americans make up about 13% of the
US population but account for 42% of HIV infections. In
2018, the rate of diagnosis of new HIV infections among
Black Americans was 39.2 per 100,000, as compared with 4.8
among whites and 13.3 in the population as a whole. This
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disparity was even greater in women: The rate of new HIV
diagnoses was 21.3 per 100,000 for Black women, nearly 13
times higher than the rate of 1.7 in white women. Moreover,
the risk of death for Black Americans from HIV/AIDS is
approximately 9 times that of their white counterparts.1,2
These and other racial disparities show the impacts of
structural racism, which contribute to myriad inequities
including access to systems of health care, education, and
employment. Within the health care system, interpersonal
discrimination based on race, gender, and sex also results in
disparities in health outcomes.3–5 The social factors and
structural inequalities that confound racial health disparities in
the United States are challenging to disentangle6 and likewise
may complicate clinical decision-making for patients with
HIV despite evidence that neither race nor ethnic origin plays
a signiﬁcant role in HIV treatment outcomes when health care
is more equitably distributed.7,8 And yet, despite overrepresentation in the US HIV epidemic and clinical need to address
health disparities, in clinical trials of HIV treatment regimens,
Black people living with HIV (PLWH) are consistently
underrepresented.9–11 As a result, the ﬁndings of clinical
trials may not necessarily be generalizable to
Black Americans.
The single-tablet regimen of the integrase strand transfer inhibitor (INSTI) bictegravir plus the nucleoside reverse
transcriptase inhibitors (NRTIs) emtricitabine and tenofovir
alafenamide (B/F/TAF) is a recommended initial treatment
for most people with HIV.12–14 Four randomized international
trials have established that switching to B/F/TAF from other
combination antiretroviral (ARV) regimens is safe and
effective in a general population of virologically suppressed
adults with and without resistance to NRTIs.15–18 Although
the B/F/TAF clinical trials of treatment-naive PLWH enrolled
relatively representative proportion of Black participants in
the United States, the inclusion of Black PLWH in treatmentexperienced studies was low. There is a clear need for clinical
data focusing on the safety and efﬁcacy of B/F/TAF switch in
virologically suppressed Black American PLWH.
The primary objective of this phase 3b study was to
evaluate the efﬁcacy of switching from a regimen of 2 NRTIs
and a third agent to a ﬁxed-dose combination of B/F/TAF vs
continuing their baseline regimen in virologically suppressed
adults self-identifying as African American or Black.

METHODS
Study Design and Participants
This randomized, open-label, multicenter, activecontrolled, phase 3b trial was conducted at 82 outpatient
centers in the United States. We enrolled adults (aged 18
years and older) living with HIV who self-described as
Black, African American, or mixed race that included Black.
Eligible participants had documented plasma HIV-1 RNA
levels ,50 copies/mL for at least 12 months before
screening while on a stable ARV regimen other than B/F/
TAF that consisted of any 2 NRTIs along with an allowed
third agent for at least 6 months. Participants had an
estimated glomerular ﬁltration rate (eGFR) $50 mL
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per minute (calculated by the Cockcroft–Gault equation)
and no documented history of resistance to INSTIs or tenofovir (TFV) resistance deﬁned as K65R/E/N
mutations, $3 thymidine analog mutations, or T69 insertions (See Appendix, Supplemental Digital Content, http://
links.lww.com/QAI/B674).
Participants were randomized (2:1 ratio) to either
switch to B/F/TAF (50 mg/200 mg/25 mg) administered
orally once daily without regard to food or stay on baseline
regimen (SBR) (which was not provided by the study) from
day 1 until week 24. After week 24, the SBR group switched
to B/F/TAF for an additional 24 weeks. Participants who
completed the study through week 48 and wished to continue
B/F/TAF were given the option to receive B/F/TAF for up to
an additional 24 weeks in an extension phase and attend study
visits every 12 weeks. Randomization was stratiﬁed by the
baseline third-agent ARV class at entry.
This trial was undertaken in accordance with the
Declaration of Helsinki and approved by central or sitespeciﬁc review boards or ethics committees. All participants
provided written informed consent.
A computer-generated allocation sequence (block size
of 6) was created by Bracket (San Francisco, CA). Study
investigators determined eligibility, obtained a participant
number, and received automated treatment assignment based
on a randomization sequence.

Procedures
Participants had visits on day 1, weeks 4, 12, 24, 36,
and 48, with an additional week 28 visit for the SBR group.
Laboratory tests included hematological analyses, serum
chemistries, cluster of differentiation-4 (CD4) T-cell counts,
renal parameters (eGFR) (Covance Laboratories, Indianapolis, IN), and measurement of HIV-1 RNA plasma concentration (Roche TaqMan 2.0; Roche Diagnostics, Indianapolis,
IN). Resistance testing by genotyping and phenotyping
integrase and reverse transcriptase (Monogram Biosciences,
Inc., South San Francisco, CA) was included for any
participant with plasma HIV-1 RNA $200 copies/mL at
conﬁrmed virologic failure and who did not resuppress on
study drug.
Safety was assessed by physical examinations, laboratory tests, recording of concomitant drugs, and recording of
adverse events, which were coded using the Medical
Dictionary for Regulatory Activities (MedDRA, version
22.1). Relatedness of adverse events to study treatment was
determined by the investigator.

Outcomes
The primary efﬁcacy endpoint was the proportion of
participants with HIV-1 RNA $50 copies/mL at week 24 as
deﬁned by the US FDA-deﬁned snapshot algorithm. The
secondary efﬁcacy endpoints were the proportion of participants with HIV-1 RNA $50 copies/mL at week 48, the
proportion of participants with HIV-1 RNA ,50 copies/mL
at weeks 24 and 48, and the change in CD4 cell count from
baseline to weeks 24 and 48.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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Statistical Analysis
The study was powered using expected efﬁcacy based on
a pooled analysis of Black participants in studies of INSTIbased regimens.19 Assuming equal efﬁcacy between the 2
treatment groups, a sample size of 480 participants randomized
in a 2:1 ratio (320 in the B/F/TAF group and 160 in the SBR
group) would achieve approximately 89% power to detect a
prespeciﬁed noninferiority margin difference of 6% in the
group proportions with HIV-1 RNA $50 copies/mL at week
24 (B/F/TAF minus SBR) by FDA snapshot algorithm, using a
1-sided alpha level of 0.025%. All randomized participants
who received at least one dose of study treatment (either B/F/
TAF or baseline regimen) on or after day 1 and did not have
pre-existing INSTI resistance-associated mutations based on
historical data were included in the primary efﬁcacy analysis.
The proportion with HIV-1 RNA $50 copies/mL was also
assessed at week 48 as a secondary outcome. The proportions
of participants with plasma HIV-1 RNA ,50 copies/mL at
weeks 24 and 48 by FDA snapshot algorithm were prespeciﬁed
secondary efﬁcacy outcomes, analyzed similarly to the primary
efﬁcacy endpoint but using a noninferiority margin of 10%.
Pre-existing drug resistance was assessed by cumulative
historical and/or proviral DNA genotypes performed retrospectively from baseline samples. We performed subgroup analyses
of the participants with plasma HIV-1 RNA ,50 copies/mL at
week 24 based on age, sex, baseline NRTI resistance, and
speciﬁcally baseline M184V/I resistance. A per-protocol analysis was performed as a secondary outcome to assess proportions
of participants with plasma HIV-1 RNA ,50 copies/mL at
week 24 by FDA snapshot algorithm. Weeks 24 and 48
secondary efﬁcacy endpoints were also analyzed with a plasma
HIV-1 RNA threshold of ,20 copies/mL by FDA snapshot
algorithm. We imputed missing as failure (M = F) and missing
as excluded (M = E) to estimate the proportion of participants
with plasma HIV-1 RNA ,50 copies/mL at weeks 24 and 48.
Differences in percentages of participants with HIV-1
RNA ,20 copies/mL, , 50 copies/mL or $50 copies/mL
between treatment groups and 95% CI were calculated based
on exact methods.
An analysis of variance model with treatment group as
a ﬁxed effect was used to analyze CD4 count and percentage.
Safety was assessed in all randomized participants who
received at least one dose of study treatment. Differences
between groups in fasting lipids and body weight were tested
using the two-sided Wilcoxon rank-sum test. Safety data were
collected from the date the study drug was ﬁrst given for up to
30 days after the last dose of study drug. Treatment
satisfaction questionnaire scores were compared between
groups using analysis of covariance adjusting for
baseline score.
We used SAS Software Version 9.4 (SAS Institute Inc.,
Cary, NC) for all analyses. This study was conducted
according to protocol and is registered with ClinicalTrials.
gov, number NCT03631732.

RESULTS
Between August 28, 2018, and March 6, 2019, 558
individuals were screened for enrollment and 496 were
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randomized: 331 to B/F/TAF and 165 to SBR. One participant randomized to B/F/TAF never received treatment and
was excluded from analysis. Of 330 participants randomized
and treated with B/F/TAF, 320 (97%) continued treatment
after the week 24 primary endpoint, and 163 of 165 (99%)
participants randomized to SBR switched to B/F/TAF at week
24 (Fig. 1). Demographics and baseline characteristics were
generally balanced between groups (Table 1). The median age
overall was 49 years, 32% were ciswomen, 2% transwomen,
and 10% had documented baseline M184V/I mutation.
Median time on HIV treatment was 10 years, and median
time on baseline ARV regimen was 2 years. Most participants
(61%) were receiving an INSTI as a third agent at baseline.

Efficacy
Switching to B/F/TAF was noninferior to SBR for the
primary outcome of proportion of participants with plasma
HIV-1 RNA $50 copies/mL at week 24 as deﬁned by the US
FDA snapshot algorithm {0.6% (2 of 328 participants) vs
1.8% (3 of 165), difference 21.2% (95% conﬁdence interval
[CI]: 24.8% to 0.9%)} (Table 2, Fig. 2, panel A). Two
participants were found to have baseline INSTI resistance
based on historical genotype data and were excluded from the
primary analysis because of this protocol violation; 1
participant each with Y143C and Q148K mutations, both
were randomized to B/F/TAF and had HIV-1 RNA ,50
copies/mL at week 24. The secondary efﬁcacy outcome of
proportion of participants with plasma HIV-1 RNA ,50
copies/mL at week 24 was consistent with the primary
endpoint and showed high rates of virologic suppression
[B/F/TAF 96.3% (316 of 328 participants) vs SBR 94.5%
(156 of 165)] (Table 2).
After 48 weeks of receiving B/F/TAF, 95% (310 of
328) in the group randomized to B/F/TAF had HIV-1
RNA ,50 copies/mL (Fig. 2, panel A; Appendix Table 4,
Supplemental Digital Content, http://links.lww.com/QAI/
B674). Two had HIV-1 RNA $50 copies/mL. One individual
had an HIV-1 RNA level of 55 copies/mL at week 48 and
switched back to the prestudy regimen. The other had an
HIV-1 RNA level of 455 copies/mL at week 48, which
resuppressed on continued treatment with B/F/TAF; no
treatment-emergent resistance was detected. Of 163 participants randomized to SBR who switched to B/F/TAF at week
24, no participants had HIV-1 RNA $50 copies/mL; 158
(97%) had HIV-1 RNA ,50 copies/mL at week 48.
Results from the per-protocol, M = F, and M = E
analyses conducted at weeks 24 and 48 were consistent with
the primary outcome (Table 2). Analysis of the proportion of
participants with plasma HIV-1 RNA ,20 copies/mL showed
high and similar rates of virologic suppression at this lower
threshold. Efﬁcacy between B/F/TAF and SBR was similar
across prespeciﬁed subgroups (Fig. 2, panel B), and testing
for homogeneity found no signiﬁcant interactions between
treatment and subgroup. We observed no treatment differences in changes from baseline in CD4 cell count and CD4
percentage at week 24 (see Appendix Table 1, Supplemental
Digital Content, http://links.lww.com/QAI/B674).

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 1. Baseline Demographics and Disease Characteristics

B/F/TAF
(n = 330)

SBR (Delayed
Switch to B/F/
TAF)
(n = 165)

Median age, yrs (range)
49 (18–79)
49 (19–70)
Female sex at birth, n (%)
101 (31)
55 (33)
Gender identity, n (%)
Cisgender
317 (96)
159 (96)
Transgender
6 (2)
6 (4)
Other gender or prefer not to disclose
7 (2)
0
Sexual orientation, n (%)
Heterosexual (female sex at birth)
97 (29)
52 (32)
Heterosexual (male sex at birth)
62 (19)
41 (25)
Gay or bisexual (male sex at birth)
162 (49)
67 (41)
Ethnicity, n (%)
Hispanic/latinx
15 (5)
5 (3)
Median CD4 count, cells/mL (Q1, Q3)
747 (570, 922) 758 (494, 969)
Median eGFRCG, mL/min (Q1, Q3)
110 (88, 132)
107 (86, 132)
Median weight, kg (Q1, Q3)
88 (79, 103)
89 (76, 104)
29.2 (25.9,
29.3 (25.7, 34.3)
Median BMI, kg/m2 (Q1, Q3)
34.0)
HBV coinfection, n (%)
15 (5)
3 (2)
Baseline NRTI backbone,* n (%)
F/TAF
224 (68)
107 (65)
F/TDF
56 (17)
34 (21)
Abacavir/lamivudine
44 (13)
24 (15)
Other
4 (1)
0
Baseline 3rd agent,† n (%)
INSTI
202 (61)
99 (60)
NNRTI
100 (30)
51 (31)
PI
30 (9)
14 (9)
CCR5 antagonist
0
1 (1)
Baseline ARV resistance,‡ n (%)
NRTI resistance
44 (13)
26 (16)
M184V/I
31 (9)
20 (12)
NNRTI resistance
70 (21)
32 (19)
PI resistance
36 (11)
26 (16)
INSTI resistance
8 (2)
3 (2)
*Two participants in the B/F/TAF group did not report a baseline NRTI backbone
medication; both were protocol violations.
†One participant in the B/F/TAF group reported both PI and INSTI; 1 subject in the
B/F/TAF group reported both INSTI and NNRTI; both were protocol violations.
‡No baseline ARV resistance data B/F/TAF n = 17, SBR n = 7. Resistance assessed
by cumulative historical or retrospective baseline proviral DNA genotypes.
BMI, body mass index; CCR5, C-C chemokine receptor type 5; eGFRCG, estimated
glomerular ﬁltration rate (calculated by Cockcroft–Gault equation); HBV, hepatitis B
virus; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Q,
quartile.

At baseline, 13% (44 of 328) in the B/F/TAF group and
16% (26 of 165) in the SBR group had NRTI resistance,
including 9% (31 of 328) and 12% (20 of 165) with M184V/I
mutations in the B/F/TAF and SBR groups, respectively.
Efﬁcacy by snapshot analysis was similar in participants with
or without NRTI resistance (Fig. 2, panel C). Among
participants with NRTI resistance at baseline 98% (43 of
44) on B/F/TAF and 96% (25 of 26) on SBR had HIV-1
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RNA ,50 copies/mL at week 24. Among participants with
M184V or I mutations at baseline 97% (30 of 31) on B/F/
TAF and 95% (19 of 20) on SBR had HIV-1 RNA ,50
copies/mL at week 24. One participant with M184V on B/F/
TAF discontinued after the baseline visit and did not have
virologic data at week 24. In addition, 2% (8 of 328) in the B/
F/TAF group and 2% (3 of 165) in the SBR group had
primary INSTI resistance detected at baseline, all of whom
had HIV-1 RNA ,50 copies/mL at week 24.
Altogether, 68 participants with baseline NRTI resistance (including 50 with M184V/I) received B/F/TAF
during the study and had postswitch virologic data. At study
week 48, all 68 (100%) had HIV-1 RNA ,50 copies/mL; 43
randomized to B/F/TAF had 48 weeks of treatment, and 25
with a delayed switch from SBR had 24 weeks of treatment
with B/F/TAF. In addition, a total of 11 participants with
baseline INSTI resistance received B/F/TAF, and all 11
(100%) had HIV-1 RNA ,50 copies/mL at week 48.
One participant in each treatment group met criteria for
resistance testing through week 24. No treatment-emergent
resistance to any components of the regimens was detected in
either group during the study.

Safety
Through week 24, 64% of participants who switched
to B/F/TAF (210 of 330) experienced at least one adverse
event compared with 52% (85 of 165) of those on SBR
(Table 3). The most common adverse events in the B/F/
TAF and SBR groups were upper respiratory infection,
diarrhea, cough, arthralgia, and bronchitis. The proportion
of participants who experienced at least one grade 3 or 4
adverse event was the same in both groups (5%) as was the
proportion of participants experiencing a serious adverse
event (4%). Investigators attributed events to treatment in
11% (36 participants) in the B/F/TAF group and none in
the SBR group. For most participants who had adverse
events attributed to treatment, events were either mild (25
of 36) or moderate (8 of 36) and resolved on treatment.
Three of these 36 participants experienced grade 3 events:
one (somnolence) that resolved on study drug and 2 that
led to study drug discontinuation (headache n = 1, agitation, psychomotor hyperactivity, and anxiety n = 1). In
total, 7 (2%) of participants in the B/F/TAF group and
none in the SBR group had adverse events leading to
discontinuation up to week 24. No deaths or pregnancies
were reported.
Incidence of grade 3 or 4 laboratory abnormalities through
week 24 was comparable between groups: 8% (27 of 329) B/F/
TAF and 6% (10 of 165) SBR (see Appendix Table 2,
Supplemental Digital Content, http://links.lww.com/QAI/B674).
Median [interquartile range (IQR)] change from baseline in
eGFR at week 24 was 24.6 (212.1, 2.6) mL/min for B/F/TAF
(n = 318) vs 1.1 (27.1, 7.8) mL/min for SBR (n = 160);
P , 0.001; consistent with the previously described inhibition of
tubular secretion of creatinine without affecting renal glomerular
function by bictegravir. In the B/F/TAF group, one participant
with prostate cancer discontinued study drug because of acute
kidney injury secondary to urinary obstruction with

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 1. CONSORT diagram. B/F/TAF, bictegravir, emtricitabine, and tenofovir alafenamide; SBR, stay on baseline regimen.
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TABLE 2. Virologic Outcomes at Week 24, Full Analysis Set
Week 24
HIV-1 RNA ,50 copies/mL
HIV-1 RNA $50 copies/mL
HIV-1 RNA $50 copies/mL
Discontinued because of lack of efﬁcacy
Discontinued study drug because of AE/death and last
available HIV-1 RNA $50 copies/mL
Discontinued because of other reasons† and last
available HIV-1 RNA $50 copies/mL
No virologic data in the week 24 window
Discontinued because of AE/death and last available
HIV-1 RNA ,50 copies/mL
Discontinued because of other reasons† and last
available HIV-1 RNA ,50 copies/mL
Missing data but on study drug
HIV-1 RNA ,50 copies/mL by per-protocol snapshot
analysis‡
HIV-1 RNA ,50 copies/mL by missing = failure§
HIV-1 RNA ,50 copies/mL by missing = excluded§
HIV-1 RNA ,20 copies/mL
Hepatitis B virus DNA ,29 IU/mL by
missing = excludedk

B/F/TAF
(n = 328)

SBR (No Switch)
(n = 165)

316 (96.3%)
2 (0.6%)
2 (0.6%)
0
0

156 (94.5%)
3 (1.8%)
3 (1.8%)
0
0

0

0

10 (3.0%)
6 (1.8%)

6 (3.6%)
0

4 (2.1%)

1 (0.6%)

0
304/306 (99.3%)

5 (3.0%)
145/148 (98.0%)

321/328 (97.9%)
321/323 (99.4%)
305/328 (93.0%)
6/7 (86%)

156/165 (94.5%)
156/159 (98.1%)
149/165 (90.3%)
1/1 (100%)

B/F/TAF vs SBR
Difference in Percentages (95% CI)*
1.8% (22.0% to 6.8%)
21.2% (24.8% to 0.9%)

1.4% (21.0% to 5.3%)
3.3% (20.2% to 8.2%)
1.3% (20.8% to 4.9%)
2.7% (22.4% to 8.7%)

Data are n (%).
Virology outcomes are based on snapshot algorithm unless otherwise speciﬁed.
The week 24 window is between days 127 and 210 (inclusive).
Per-protocol analysis excluded patients in full analysis set who were off study drug at week 24 or had low adherence, that is, adherence #2.5th percentile among those in study or
did not meet the inclusion criteria for baseline ARV medication or met inclusion/exclusion criteria for mutations detected before baseline or after baseline.
*The difference in percentages of participants between treatment groups and their 95% CIs were calculated based on exact methods.
†Other reasons include participants who discontinued study drug because of investigator’s discretion, subject decision, lost to follow-up, noncompliance with study drug, protocol
violation, pregnancy, and study terminated by sponsor.
‡The per-protocol analysis was performed in a similar manner to the primary endpoint but excluded participants with low adherence (below the 2.5th percentile), violation of key
entry criteria, or who did not have a plasma HIV-1 RNA value in the week 24 analysis window because of reasons other than lack of efﬁcacy.
§Difference in percentages and 95% CI were based on a dichotomized response: HIV-1 RNA ,50 copies/mL vs HIV-1 RNA $50 copies/mL or missing for missing = failure
approach and HIV-1 RNA ,50 copies/mL vs HIV-1 RNA $50 copies/mL for missing = excluded approach.
kAt baseline, 18 participants had HBV coinfection: 15 (5%) in the B/F/TAF group and 3 (2%) in the SBR group. At baseline, 13 of 15 in the B/F/TAF group and 2 of 3 in the SBR
group had HBV DNA ,29 IU per mL. The denominator for percentage is the number of participants in the full analysis set with HIV/HBV coinfection and with nonmissing HBV
DNA at week 24.

hydronephrosis; this adverse event was judged by the investigator
as not related to study drug. There were no discontinuations
because of renal adverse effects in the SBR group and no
reported cases of proximal renal tubulopathy in either group.
A cumulative analysis of safety was performed for all 493
participants treated with B/F/TAF when the last participant
reached the week 48 endpoint. At the time of the analysis, the
median (IQR) exposure to B/F/TAF was of 61 (56–68) weeks
among those randomized to B/F/TAF and 38 (32–44) weeks for
those with delayed switch to B/F/TAF; B/F/TAF was well
tolerated during the study. Overall, 367 (74%) had at least one
adverse event (see Appendix Table 5, Supplemental Digital
Content, http://links.lww.com/QAI/B674). Three individuals
who received B/F/TAF discontinued treatment after week 24
because of adverse events. Grade 3 or 4 laboratory abnormalities
were reported for 60 participants (12%). One death was reported
because of a gunshot wound; no pregnancies were reported.
Participants randomized to the B/F/TAF group had higher
baseline levels of fasting total and low-density lipoprotein
cholesterol and triglycerides compared with those randomized to

SBR (P = 0.006 P = 0.02, and P = 0.03, respectively) (see
Appendix Table 3, Supplemental Digital Content, http://links.
lww.com/QAI/B674). At week 24, treatment differences in
changes from baseline were small but statistically signiﬁcant
for fasting total cholesterol (25-mg/dL B/F/TAF vs 22-mg/dL
SBR; P = 0.006), high-density lipoprotein cholesterol (22-mg/
dL B/F/TAF vs 21-mg/dL SBR; P = 0.05), and triglycerides
(25 vs 3 mg/dL; P = 0.01). No signiﬁcant treatment
differences were noted for changes from baseline in lowdensity lipoprotein cholesterol or total cholesterol:high-density
lipoprotein ratio at week 24. A similar proportion of participants in each group were taking lipid-lowering medication at
baseline and initiated lipid-lowering agents through week 24.
In sensitivity analyses excluding participants on lipid-lowering
medications, changes from baseline in fasting lipids were
consistent with the full analyses.
Median (IQR) weight at baseline was 88 (79–103) kg in
the B/F/TAF group and 89 (76–104) kg in the SBR group
(P = 0.66), corresponding to a median (IQR) body mass index
of 29 (26–34) in each group. Median (IQR) weight change
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FIGURE 2. Virologic outcomes. A, FDA
Snapshot algorithm. B, Treatment differences based on prespecified subgroups at week 24: HIV-1 RNA ,50
copies/mL. C, Virologic outcomes at
weeks 24 and 48 by baseline resistance
profile.

from baseline at week 24 was +0.9 (21.3, +3.0) kg in the B/
F/TAF group and +0.2 (21.7, +2.0) kg in the SBR group
(P = 0.09). At week 48, median (IQR) change in body weight
remained at 0.9 kg (21.5, 4.1) in the B/F/TAF arm. Post hoc
exploratory analyses of the change in weight were performed
in subgroups by sex at birth for all participants and by
baseline NRTIs in those switched to B/F/TAF (see Appendix
Fig. 1, Supplemental Digital Content, http://links.lww.com/
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QAI/B674). In the male sex at birth subanalysis, median
change in weight from baseline was similar between groups.
Among female sex at birth participants, a treatment difference
was noted in median (IQR) change in weight from baseline at
week 24 [+1.0 (21.4, 2.7) kg B/F/TAF, 20.4 (21.8, 1.2) kg
SBR; P = 0.03]. Participants who switched to B/F/TAF from
a TFV disoproxil fumarate (TDF)-containing regimen had
median (IQR) weight gain of +1.8 (20.8, 4.3) kg at week 24
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TABLE 3. Safety Through Week 24

Any adverse event
Adverse events in .3% of participants
Upper respiratory tract infection
Diarrhea
Cough
Arthralgia
Bronchitis
Grade 3 or 4 adverse event
Serious adverse event
Adverse event leading to study drug
discontinuation*
Treatment-related adverse event
Death
Laboratory abnormalities
Of any grade
Grade 3
Grade 4

B/F/TAF
(n = 330)

SBR
(No
Switch)
(n = 165)

210 (64)

85 (52)

20 (6)
11 (3)
9 (3)
11 (3)
5 (2)
17 (5)
13 (4)
7 (2)

6
5
6
2
7
8
7

(4)
(3)
(4)
(1)
(4)
(5)
(4)
0

36 (11)
0

0
0

215 (65)
24 (7)
3 (1)

111 (67)
10 (6)
0

Data are n (%).
*Adverse events leading to study drug discontinuation in the B/F/TAF group
included nightmare† (n = 1); headache† (n = 1); acute kidney injury (n = 1); diarrhea,†
dry mouth,† psychomotor hyperactivity,† agitation,† anxiety,† and insomnia† (n = 1);
abdominal distension† and ﬂatulence† (n = 1); diarrhea† (n = 1); and migraine† (n = 1).
†Reported as treatment related.

compared with +0.8 (21.3, 2.5) kg and +0.7 (22.0, 3.0) kg
for those taking TAF- and abacavir (ABC)-containing
regimens respectively (P = 0.0235 TDF vs TAF; P = 0.89
ABC vs TAF).
Among the 18 HIV/HBV-coinfected participants, there
were no hepatic adverse events, no grade 3 or 4 adverse
events, and no participants interrupted or discontinued their
study regimen because of an adverse event.
Based on responses using the HIV Treatment Satisfaction Questionnaire, median (IQR) scores were higher with B/
F/TAF than SBR at week 24 [29 (24–30) vs 28 (7–30),
P , 0.001], indicating a small but signiﬁcant difference
favoring switch to B/F/TAF.

DISCUSSION
In this randomized, open-label, multicenter trial, we
found that virologically suppressed Black adults with HIV
in the United States can switch from a regimen of 2 NRTIs
plus a third agent to B/F/TAF with no loss of virologic
efﬁcacy. Few of those who switched to B/F/TAF had HIV
RNA $50 copies/mL through week 48, and the rate of
virologic suppression was high in those with pre-existing
resistance to NRTIs. None of the participants experienced
treatment-emergent resistance. Treatment satisfaction was
higher for participants after switching to B/F/TAF.
Community advisors who participated in the study
design and oversight set goals of inclusion based on sex at
birth, gender, and sexual orientation to ensure representa-

B/F/TAF in Black Americans With HIV

tive inclusion of Black Americans with HIV. Study sites
were speciﬁcally selected to mirror the HIV epidemic
among Black PLWH in the United States. In doing so,
more than 62% of participants were enrolled in Southern
states, as deﬁned by the CDC, with others mainly from
urban areas with a high prevalence of HIV among Black
people. Despite meeting the enrollment goals, the size of
some individual subgroups of participants, particularly
transgender or other nonbinary gender groups in the study,
remains small and insufﬁcient for meaningful subanalyses.
The impacts of structural racism and inequities in access to
health care and medical research for Black Americans20 are
magniﬁed among Black transgender PLWH, and better data
on which to inform their clinical care should remain
a priority.
Our study enrolled participants on a variety of treatment
regimens and included those with a history of treatment
failure or with documented resistance to NRTIs, both patient
groups are commonly seen in clinical practice but often
excluded from clinical trials. Pre-existing NRTI resistance,
including the M184V/I mutation, did not impact the efﬁcacy
of switching to B/F/TAF.
Participants in both groups gained weight while on study,
and there was no difference in weight gain from baseline between
those randomized to B/F/TAF vs SBR. For those starting B/F/
TAF, weight gain was 0.9 kg in the ﬁrst 24 weeks and plateaued
thereafter. In subgroup analyses, cisgender women and those
previously on TDF-containing regimens switching to B/F/TAF
had greater weight gain compared with those on SBR; treatment
differences in weight gain were not signiﬁcant for men. TDF has
been associated with weight suppression in studies of both
treatment and HIV pre-exposure prophylaxis or PrEP.18,22,23–26
The large variety of baseline regimens precluded meaningful
description of the inﬂuence each may have on weight. Altogether, these ﬁndings do not suggest a substantial weight gain for
Black men and women changing to B/F/TAF.
Limitations to this trial include its open-label design.
Although this design is unlikely to have affected the primary
endpoint, which is a laboratory value not subject to bias, it
may have biased the reporting of adverse events, both by
participants and investigators.
The safety proﬁle of B/F/TAF was consistent with that
observed in other phase 3 studies. In the randomized phase,
incidence of any adverse event and treatment-related adverse
events was higher with B/F/TAF than SBR; however, this
ﬁnding is not unexpected in our open-label trial and common
in open-label studies in which a switch to a new drug is
compared with continuing a previously well-tolerated baseline regimen because of reporting bias on the part of
participants as well as ascertainment or attribution bias on
the part of investigators.16,21 Most events were mild, and the
proportions of individuals who experienced grade 3 or 4
adverse events and serious adverse events were the same in
both groups. Less than 2% of all individuals (9 of 493) who
switched to B/F/TAF had adverse events leading to discontinuation of treatment.
Overall, our results demonstrate that, among Black
Americans living with HIV, switching to B/F/TAF from a
variety of baseline suppressive regimens was efﬁcacious
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and safe. Results from this study complement those from
other large clinical trials that demonstrated the efﬁcacy,
tolerability, and lack of resistance of B/F/TAF. Our results
draw us closer to fulﬁlling a critical need to evaluate
infectious disease treatments in a disproportionately
affected population.27

CONCLUSION
B/F/TAF is safe and effective for Black Americans with
HIV switching from a variety of regimens, including those
with TFV sensitivity but pre-existing NRTI resistance.

NOTES
Community advisors representing HIV advocacy and
care organizations across North America reviewed the
protocol, provided input into study design, contributed to
training for study personnel, and set goals for inclusion
across participant groups according to sex at birth, gender
identity, and sexual orientation. A study advisory committee composed of 3 community advisors, and 3 clinical site
personnel provided ongoing monitoring and input throughout the study.
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